Vasculotide Tie2 Agonist Lung Endothelial Protection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for influenza, particularly severe cases, are inadequate as antiviral drugs have limited efficacy when administered late and are complicated by resistance, and existing therapies fail to effectively target the lung endothelium, leading to high mortality and complications from pulmonary issues and bacterial superinfections.
Innovation Solution
Administration of a multimeric Tie2 agonist, known as Vasculotide, which binds to and activates the Tie2 receptor, reducing lung endothelial leak and increasing survival even when given after infection onset, and when combined with antiviral agents, enhances treatment efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antiviral drugs are administered early, then efficacy is improved, but treatment window is limited and resistance develops
Solution Approach 1:
The patent applies preliminary action by administering the Tie2 agonist (Vasculotide) to protect the lung endothelium before bacterial superinfection can occur. This pre-protection of the endothelial barrier prevents the subsequent harmful effects of bacterial infection, allowing effective treatment even when given after the initial viral infection has progressed. The Tie2 agonist primes the endothelium to resist permeability changes that would otherwise occur with bacterial superinfection.
2Adaptability or versatility
If antiviral drugs are administered late, then treatment flexibility is improved, but efficacy is reduced
Solution Approach 1:
The Tie2 agonist is administered in advance to establish protective effects on the lung endothelium before the critical period of bacterial superinfection. This preliminary endothelial protection creates a therapeutic window that extends beyond the traditional antiviral treatment window, allowing effective intervention even when antiviral drugs are given late.
Solution Approach 2:
The Tie2 agonist acts as a cushioning agent that protects the lung endothelium from the harmful effects of bacterial superinfection. By strengthening the endothelial barrier function in advance, it cushions against the permeability increases and lung injury that would otherwise occur when bacteria superinfect the virus-infected lung, thereby extending the effective treatment period.
3Device complexity
If existing therapies target only epithelium, then viral infection treatment is simplified, but lung endothelial damage is not addressed
Solution Approach 1:
The Tie2 agonist (Vasculotide) provides multi-functionality by simultaneously protecting both the lung epithelium and endothelium. While traditional antivirals target only the epithelial viral infection, the Tie2 agonist adds endothelial protection against bacterial superinfection and permeability changes, creating a dual-protection therapy that addresses both compartments of the lung without significantly increasing treatment complexity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Vasculotide increases survival and decreases mortality in influenza-infected animals by reducing lung endothelial leak and preventing priming-induced vascular permeability, even when administered late, and when used with antiviral agents, maintains the efficacy of antiviral treatment.
Implementation Method 1
a multimeric Tie2 agonist, known as Vasculotide, which binds to and activates the Tie2 receptor
Data Source
AI summary
The present disclosure provides methods and uses of Tie2 agonists alone or in combination with antiviral agents. In particular, the present disclosure provides methods and uses for treating influenza, treating a bacterial superinfection associated with influenza and decreasing lung endothelial leakage. The disclosure also provides compositions comprising (a) a Tie2 agonist and (b) an antiviral agent and methods and uses thereof.